SX-682 NEW
| Price | $34 | $80 | $122 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-11 |
Product Details
| Product Name: SX-682 | CAS No.: 1648843-04-2 |
| Purity: 99.26% | Supply Ability: 10g |
| Release date: 2026/06/11 |
Product Introduction
Bioactivity
| Name | SX-682 |
| Description | SX-682 is an orally available allosteric inhibitor of CXCR1 and CXCR2 that blocks tumor myeloid suppressor cell recruitment and enhances T cell activation and anti-tumor immunity, with the potential to treat castration-resistant prostate cancer. |
| In vitro | SX-682 significantly inhibits PMN-MDSC trafficking without altering CXCR2 ligand expression; combination with SX-682 enhances tumor growth inhibition or established tumor rejection following programmed death axis (PD-axis) immune checkpoint blockade or adoptive cell transfer of engineered T cells; CXCR1/2 are expressed on tumor cells, but SX-682 appears to have little direct antitumor effect on these cancer cells. [1] |
| In vivo | METHODS: SX-682 (500 mg/kg, oral, one week) was used to treat tumor suppressor model mice injected subcutaneously with MOC2 cells, and PMN-MDSC accumulation was evaluated by flow cytometry. RESULTS SX-682 significantly reduced PMN-MDSC trafficking into MOC2 tumors, but SX-682 treatment did not alter the proliferation of tumor PMN-MDSC in tumor-bearing mice. The main mechanism of SX-682 is to inhibit PMN-MDSC trafficking into MOC2 tumors. [2] |
| Storage | Store at low temperature,Keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (10.7 mM), Sonication is recommended. DMSO : 130 mg/mL (278.25 mM), Sonication is recommended. |
| Keywords | tumor | SX-682 | SX682 | SX 682 | suppressor | recruitment | myeloid-derived | MDSCs | Inhibitor | inhibit | immunity | CXCR2 | CXCR1 | CXCR | CXC chemokine receptors | cells | antitumor | allosteric |
| Inhibitors Related | AZD8309 | rac-NBI-74330 | Tannic acid | Artemotil | CXCR2-IN-1 | Kynurenic acid | Soquelitinib | Plerixafor octahydrochloride | Tanimilast | 3-Indoleglyoxylic acid | Nicotinamide N-oxide | CXCL-CXCR1/2-IN-1 |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Prostate Cancer Compound Library | Immuno-Oncology Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-05-11 | ||
| $2500.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-05-11 | |
| $180.00 |
Hebei Yanxi Chemical Co., Ltd.
|
2025-06-20 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY